MENLO PARK, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight ...

Just before Christmas and, critically, after announcing some positive data, Forty Seven sat down at Gilead Sciences' HQ with its C-suite to talk M&A. Gilead liked what it saw, according to a recent ...

Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Forty Seven, Inc.

(Reuters) - Gilead Sciences Inc said on Monday it would buy Forty Seven Inc for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs.

Forty Seven Inc (NASDAQ: FTSV) shares were skyrocketing Monday morning, adding on to the roughly 19% gain the stock made Friday, after Gilead Sciences, Inc. (NASDAQ: GILD) agreed to buy the smaller ...

Forty Seven has raised $75 million, bringing its total haul to date up to $150 million. The series B round equips the Stanford University spinout to expand trials of its CD47-targeted approach to ...

FOSTER CITY, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Forty Seven, Inc. (Nasdaq: FTSV) announced today that the companies have entered into a definitive ...

-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and ...

Gilead Sciences and Forty Seven are reportedly tying the knot through a $4.9 billion buyout agreement. Shares of Trillium Therapeutics, a fellow CD47 drugmaker, are also jumping on this news. This is ...

Explore the Forty Seven stock price history with detailed daily historical prices, including open, high, low, close, and volume data. Review past trends, identify key price levels, and find the ...

– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell ...